Low molecular weight chitooligosaccharide inhibits infection of SARS-CoV-2 in vitro.
J Appl Microbiol
; 133(2): 1089-1098, 2022 Aug.
Article
in English
| MEDLINE | ID: covidwho-1840447
ABSTRACT
AIMS:
The discovery of antiviral substances to respond to COVID-19 is a global issue, including the field of drug development based on natural materials. Here, we showed that chitosan-based substances have natural antiviral properties against SARS-CoV-2 in vitro. METHODS ANDRESULTS:
The molecular weight of chitosan-based substances was measured by the gel permeation chromatography analysis. In MTT assay, the chitosan-based substances have low cytotoxicity to Vero cells. The antiviral effect of these substances was confirmed by quantitative viral RNA targeting the RdRp and E genes and plaque assay. Among the substances tested, low molecular weight chitooligosaccharide decreased the fluorescence intensity of SARS-CoV-2 nucleocapsid protein of the virus-infected cells in a dose-dependent manner.CONCLUSIONS:
In conclusion, the chitooligosaccharide, a candidate for natural treatment, has antiviral effects against the SARS-CoV-2 virus in vitro. SIGNIFICANCE AND IMPACT OF STUDY In this study, it was suggested for the first time that chitosan-based substances such as chitooligosaccharide can have an antiviral effect on SARS-CoV-2 in vitro.Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Chitosan
/
COVID-19 Drug Treatment
Limits:
Animals
Language:
English
Journal:
J Appl Microbiol
Journal subject:
Microbiology
Year:
2022
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS